1. Home
  2. GLPG vs RAMP Comparison

GLPG vs RAMP Comparison

Compare GLPG & RAMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galapagos NV

GLPG

Galapagos NV

N/A

Current Price

$32.47

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo LiveRamp Holdings Inc.

RAMP

LiveRamp Holdings Inc.

N/A

Current Price

$28.19

Market Cap

1.8B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
GLPG
RAMP
Founded
1999
2018
Country
Belgium
United States
Employees
704
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
N/A
1994

Fundamental Metrics

Financial Performance
Metric
GLPG
RAMP
Price
$32.47
$28.19
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$36.50
$35.60
AVG Volume (30 Days)
90.9K
885.3K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.14
Revenue
N/A
$745,580,000.00
Revenue This Year
N/A
$11.15
Revenue Next Year
N/A
$9.10
P/E Ratio
N/A
$25.48
Revenue Growth
N/A
13.02
52 Week Low
$22.59
$21.71
52 Week High
$37.78
$35.20

Technical Indicators

Market Signals
Indicator
GLPG
RAMP
Relative Strength Index (RSI) 39.01 58.35
Support Level $32.07 $27.91
Resistance Level $33.56 $28.88
Average True Range (ATR) 0.80 1.12
MACD -0.16 0.30
Stochastic Oscillator 0.00 70.49

Price Performance

Historical Comparison
GLPG
RAMP

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About RAMP LiveRamp Holdings Inc.

LiveRamp Holdings Inc is a technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics, and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust. The Company provides a data collaboration platform, essentially acting as a data collaboration hub where businesses can securely share and manage first-party consumer data with trusted partners while prioritizing data privacy and ethics.

Share on Social Networks: